Analyst Research

Report Title Price
Thomson Reuters Stock Report - BIOCON LIMITED (BIOCON-IN)
Provider: Thomson Reuters Stock Report
$25.00
Buy
Biocon Limited (BIOCON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Provider: GlobalData
$250.00
Buy
Biocon Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy
Biocon falls 0.8% in weak trading with bearish open interest
Provider: News Bites Pty Limited
$5.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Biocon Ltd Receives Marketing Authorization for Biologic Itolizumab for Psoriasis


Monday, 7 Jan 2013 10:05pm EST 

Biocon Ltd announced that it has received marketing authorization from the Drugs Controller Gereral of India (DCGI) for its Biologic Itolizumab, anti CD6 molecule, for the treatment of chronic plaque Psoriasis. Itolizumab, is a first in class therapy with a unique Mechanism of Action (MOA) and an excellent safety profile as indicated during the 52 week Phase III multi-centric clinical study conducted in India. 

Latest Developments for Biocon Ltd

Latest Key Developments in Biotechnology

Company Quote

Biocon Ltd
(BION.NS)
279.35
-3.25 -1.15%
6:26am EDT